Int J Med Sci 2020; 17(3):383-389. doi:10.7150/ijms.39775 This issue Cite

Research Paper

HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B

Chong Zhang, Zhengrong Yang, Ziyi Wang, Xiaoguang Dou, Qiuju Sheng, Yanwei Li, Chao Han, Yang Ding

Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, 110022, China

Citation:
Zhang C, Yang Z, Wang Z, Dou X, Sheng Q, Li Y, Han C, Ding Y. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B. Int J Med Sci 2020; 17(3):383-389. doi:10.7150/ijms.39775. https://www.medsci.org/v17p0383.htm
Other styles

File import instruction

Abstract

Objective: The proportion of hepatitis e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients in China has increased rapidly. However, the response of these patients to peginterferon (peg-IFN) treatment is poor, and the antiviral treatment strategies are inconsistent. This study aimed to investigate the role of hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) in early prediction of response in HBeAg-negative CHB patients receiving peg-IFN α-2a.

Patients and Methods: Treatment-naïve HBeAg-negative patients were involved in this prospective study during 2014-2018. The HBV DNA and HBsAg were quantified at baseline and during treatment (weeks 12, 24 and 48) in sera. The factors associated with HBV DNA undetectable and HBsAg <100 IU/ml at treatment 48 weeks were assessed.

Results: This study involved 45 patients. There was HBV DNA undetectable in 36 cases (80%), including 19 (52.8%) with HBsAg <100 IU/ml at week 48. The HBV DNA <2.0 log10IU/ml at week 24 (PPV = 96.9%, NPV = 66.7%, P = 0.018) was an independent predictor of HBV DNA undetectable at week 48. The HBsAg <800 IU/ml at baseline (PPV = 92.1%, NPV = 69.7%, P = 0.054) and HBsAg decline >5.00-fold at week 24 (PPV = 83.3%, NPV = 77.8%, P = 0.038) were independent predictors of HBsAg <100 IU/ml and HBV DNA undetectable at week 48.

Conclusion: Early on-treatment quantification of HBV DNA and HBsAg in patients with HBeAg-negative CHB treated with peg-IFN α-2a may help identify those likely to be cured by this method and optimize therapy strategies.

Keywords: chronic hepatitis B, HBeAg, prospective study


Citation styles

APA
Zhang, C., Yang, Z., Wang, Z., Dou, X., Sheng, Q., Li, Y., Han, C., Ding, Y. (2020). HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B. International Journal of Medical Sciences, 17(3), 383-389. https://doi.org/10.7150/ijms.39775.

ACS
Zhang, C.; Yang, Z.; Wang, Z.; Dou, X.; Sheng, Q.; Li, Y.; Han, C.; Ding, Y. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B. Int. J. Med. Sci. 2020, 17 (3), 383-389. DOI: 10.7150/ijms.39775.

NLM
Zhang C, Yang Z, Wang Z, Dou X, Sheng Q, Li Y, Han C, Ding Y. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B. Int J Med Sci 2020; 17(3):383-389. doi:10.7150/ijms.39775. https://www.medsci.org/v17p0383.htm

CSE
Zhang C, Yang Z, Wang Z, Dou X, Sheng Q, Li Y, Han C, Ding Y. 2020. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B. Int J Med Sci. 17(3):383-389.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.